PharmaEngine and Nanobiotix Sign Asia-Pacific Exclusive License and Collaboration Agreement For NBTXR3
06:30 EDT 6 Aug 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
French Nanobiotix S.A. announced today that it entered into a
strategic partnership with PharmaEngine, Inc. for the rapid development
of NBTXR3, the lead product from the NanoXray pipeline of Nanobiotix.
Nanobiotix is a nanomedi...
Other Sources for this Article
Nanobiotix
Laurent Levy
laurent.levy@nanobiotix.com
or
Akampion
Ludger
Weß, +49 40 88 16 59 64
or
Ines-Regina Buth, +49 30 23 63 27 68
info@akampion.com
More From BioPortfolio on "PharmaEngine and Nanobiotix Sign Asia-Pacific Exclusive License and Collaboration Agreement For NBTXR3"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
